Introduction
Materials and methods
Literature search
Study selection
Data extraction
Network geometry
Measures of treatment effect
Dealing with missing data
Assessment of transitivity across treatment comparisons
Methods for direct and indirect or mixed treatment comparisons
Sensitivity analysis
Results
Study selection
Pain
Treatment | Number of studies | Number of patients | Products in treatment category | Included studiesa |
---|---|---|---|---|
High MW HA—pain | 22 | 2306 | Synvisc Synvisc-one Euflexxa Gel-one Durolane | 2, 4, 6, 7, 10, 13, 14, 25, 34, 35, 36, 41, 45, 46, 47, 48, 50, 56, 57, 64, 68 |
High MW HA—function | 12 | 719 | 1, 3, 10, 11, 17, 35, 36, 37, 39, 41, 60, 65 | |
High MW HA—adverse events | 23 | 2563 | 1, 3, 4, 6, 10, 13, 25, 30, 34, 35, 36, 37, 39, 41, 42, 45, 48, 50, 56, 57, 64, 65, 68 | |
Low MW HA—pain | 35 | 2762 | Hyalgan Supartz Orthovisc Monovisc Artzal | 1, 5, 6, 9, 11, 18, 21, 22, 24, 25, 26, 29, 30, 33, 34, 35, 36, 38, 40, 41, 42, 43, 45, 46, 47, 50, 55, 57, 59, 60, 62, 64, 65, 68 |
Low MW HA—function | 11 | 645 | 5, 6, 9, 21, 35, 36, 37, 38, 41, 54, 62 | |
Low MW HA—adverse events | 37 | 2996 | 1, 6, 7, 9, 18, 19, 20, 21, 24, 25, 27, 31, 32, 34, 35, 36, 37, 38, 40, 41, 43, 44, 45, 49, 50, 52, 53, 54, 57, 58, 60, 61, 62, 63, 64, 66, 68 | |
Standard-release corticosteroidb—pain | 18 | 1019 | Triamcinolone Betamethasone Hydrocortisone Methylprednisolone Cortisone | 5, 7, 8, 10, 11, 12, 16, 23, 24, 28, 30, 33, 40, 42, 59, 60, 62, 67 |
Standard-release corticosteroidb—function | 10 | 628 | 5, 8, 10, 11, 15, 23, 54, 60, 62, 67 | |
Standard-release corticosteroidb—adverse events | 12 | 683 | 7, 8, 10, 24, 30, 40, 42, 51, 54, 60, 61, 62 | |
Extended-release corticosteroid—pain | 3 | 325 | Zilretta | 8, 15, 16 |
Extended-release corticosteroid—function | 3 | 325 | 8, 15, 16 | |
Extended-release corticosteroid—adverse events | 3 | 325 | 8, 15, 16 | |
PRP—pain | 5 | 300 | Platelet-rich plasma Autologous conditioned plasma | 13, 20, 21, 22, 55 |
PRP—function | 4 | 168 | 21, 23, 39, 55 | |
PRP—adverse events | 3 | 146 | 21, 38, 55 |